title: Posterior reversible encephalopathy syndrome after bevacizumab therapy in a normotensive patient.
abstract: Posterior reversible encephalopathy syndrome (PRES) is a neurological disorder characterised by distinct radiological features. Common precipitants of this disorder include acute medical illness, hypertensive crisis, eclampsia, immunosuppressive therapy and chemotherapy. We present the case of a patient with advanced ovarian carcinoma who developed PRES shortly after receiving bevacizumab (Avastin), an inhibitor of vascular endothelial growth factor. The patient's medical history and clinical presentation both suggest bevacizumab as the precipitator for PRES. This agent has been often overlooked as a possible cause of this rare neurological syndrome.
authors: Department of Anaesthesia, Royal Oldham Hospital, Peninne Acute Hospitals Trust, Manchester,  UK.
authors: Ola
authors: O
authors: Abbas
authors: Ali
authors: A
authors: Shamseddin
authors: Sally
authors: S
authors: Temraz
authors: Ali
authors: A
authors: Haydar
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy; D000328:Adult; D020533:Angiogenesis Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects* / Q000627:therapeutic use; D000068258:Bevacizumab; D001794:Blood Pressure; D003937:Diagnosis, Differential; D016889:Endometrial Neoplasms / Q000188:drug therapy; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008279:Magnetic Resonance Imaging; D054038:Posterior Leukoencephalopathy Syndrome / Q000139:chemically induced* / Q000175:diagnosis; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab